Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phas... by Moreno, Carol, MD, Greil, Richard, Prof, Demirkan, Fatih, Prof, Tedeschi, Alessandra, MD, Anz, Bertrand, MD, Larratt, Loree, Prof, Simkovic, Martin, MD, Samoilova, Olga, MD, Novak, Jan, MD, Ben-Yehuda, Dina, Prof, Strugov, Vladimir, MD, Gill, Devinder, MD, Gribben, John G, Prof, Hsu, Emily, PhD, Lih, Chih-Jian, PhD, Zhou, Cathy, MS, Clow, Fong, ScD, James, Danelle F, MD, Styles, Lori, MD, Flinn, Ian W, MD

Get full text

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymp... by Chanan-Khan, Asher, Prof, Cramer, Paula, MD, Demirkan, Fatih, MD, Fraser, Graeme, MD, Silva, Rodrigo Santucci, MD, Grosicki, Sebastian, Prof, Pristupa, Aleksander, MD, Janssens, Ann, MD, Mayer, Jiri, Prof, Bartlett, Nancy L, Prof, Dilhuydy, Marie-Sarah, MD, Pylypenko, Halyna, MD, Loscertales, Javier, MD, Avigdor, Abraham, MD, Rule, Simon, Prof, Villa, Diego, MD, Samoilova, Olga, MD, Panagiotidis, Panagiots, Prof, Goy, Andre, MD, Mato, Anthony, MD, Pavlovsky, Miguel A, MD, Karlsson, Claes, MD, Mahler, Michelle, MD, Salman, Mariya, PhD, Sun, Steven, PhD, Phelps, Charles, MS, Balasubramanian, Sriram, PhD, Howes, Angela, PhD, Hallek, Michael, MD

Get full text